Vincristine

CHEMBL90555 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

825.0 g/mol

LogP

2.8

Phase

4

This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors. It is given intravenously and is notable for causing peripheral neuropathy — numbness, tingling, and weakness in the hands and feet — as its main dose-limiting side effect. Accidental administration into the spinal canal (intrathecal) is invariably fatal, so strict safety protocols are in place.

分子量

825.0000 g/mol

LogP

2.80

TPSA

171.00 Å²

リピンスキーの五則

不適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1

InChI

InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1

Molecular Formula

C46H56N4O10

HBD / HBA

3 / 12

回転可能結合数

10

重原子数

60

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors. It is given intravenously and is notable for causing peripheral neuropathy — numbness, tingling, and weakness in the hands and feet — as its main dose-limiting side effect. Accidental administration into the spinal canal (intrathecal) is invariably fatal, so strict safety protocols are in place.

Yes, Vincristine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL90555. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5978. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Vincristine PillFYIで

構造

クイックデータ

分子式: C46H56N4O10

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.